Advaxis, Inc. Company Profile
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research â UK. Advaxisâ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxisâ scientific advisory board.
News Articles
Advaxis announces publication of preclinical research with ADXS-PSA
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis'...
Advaxis’ Cervical Cancer Treatment Comes to ASCO
The American Society of Clinical Oncology’s (ASCO) annual meeting is fast approaching, scheduled for May 31st to June 4th in breezy Chicago. One of the many to present data this year is Advaxis, a...
Advaxis to license its ADXS-HPV product candidate to FusionVax
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax,...
Advaxis Announces 2013 Annual Meeting of Stockholders
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that its Annual Meeting of Stockho...
Advaxis Announces Promotion of Dr. Robert Petit and Daniel J. O’Connor
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the Board of Directors of Adv...
Drugs and Medications
None
PubMed Articles
A chimeric human Her2/neu gene (ChHer2) harboring most of the known major histocompatibility complex class I epitopes of the HER2/neu oncogene was expressed as a fusion protein to a non-hemolytic frag...
Clinical Trials
None
Companies
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor...
Advaxis, Inc. and Rodman & Renshaw, LLC
Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform tech...
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate...
Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate...
Advaxis, Inc. is a biotechnology company that uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon over a 10 yea...
More Information about "Advaxis, Inc." on BioPortfolio
We have published hundreds of Advaxis, Inc. news stories on BioPortfolio along with dozens of Advaxis, Inc. Clinical Trials and PubMed Articles about Advaxis, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Advaxis, Inc. Companies in our database. You can also find out about relevant Advaxis, Inc. Drugs and Medications on this site too.
